Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University provides an overview of the professional development courses offered at the unit
Life Sciences sector responds to the Business, Energy and Industrial Strategy (BEIS) Committee report on the impact of Brexit on the pharmaceutical sector
CEO of Medicines Discovery Catapult, Chris Molloy provides a compelling analysis of pharma R&D productivity and the discovery of new medicines and the role that the SME sector can play in this
The Association of the British Pharmaceutical Industry (ABPI) – representing global pharmaceutical businesses in the UK including GSK, AstraZeneca, Pfizer and Roche – has responded to Brexit speech by Prime Minister Theresa May
Professor Jatinder Lamba from the Department of Pharmacotherapy and Translational Research gives an in-depth perspective on acute myeloid leukaemia (AML) and cytarabine pharmacogenomics
Acute myeloid...
As part of their partnership, Rhineland-Palatinate region of Germany and Rwanda foster the exchange of knowledge in hospital management, medical professions and psychiatric care...
Professor of Organic Chemistry at the University of York and Chairman of the Royal Society of Chemistry’s Heterocyclic and Synthesis Group, Peter O’Brien explores...
Prof Thomas Jaki from the Medical and Pharmaceutical Statistics Research Unit at Lancaster University explores a novel approach to Ph.D. training for those in the pharmaceutical industry
Jonathan Miles from Open Access Government explored the work the Danish Ministry of Health does to improve health policy across the country
The Danish Ministry...
The Wellcome Trust backs ideas from all over the world to improve health for everyone, as Open Access Government learns
The Wellcome Trust traces its...
Islam Elkonaissi and Zahra Laftah from the UKCPA explore the British model of supporting excellence in clinical pharmacy practice
In the UK, evidence that pharmacists...
By providing the infrastructure to support drug discovery, the IMI is accelerating access to innovative medicines, as the EFPIA highlights here
Innovation is the lifeblood...
The changing pharma landscape means opportunities for Parkinson's drug discovery are missed, but Parkinson's UK has a new strategy to redress the balance
This will...
Dr. Alexander Natz and Dr. Oliver Sude, EUCOPE outline the role small to medium sized innovative companies can play in developing pharmaceutical research
